Cytokinetics (NASDAQ:CYTK) Announces Quarterly Earnings Results

Cytokinetics (NASDAQ:CYTK) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.67), FiscalAI reports. The company had revenue of $19.36 million during the quarter, compared to analyst estimates of $8.52 million. Cytokinetics’s revenue for the quarter was up 1112.5% on a year-over-year basis. During the same period in the prior year, the business earned ($1.36) EPS.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO U.S. launch exceeded expectations in a partial quarter with $4.8M net product revenue, ~680 patients prescribed by quarter-end (1,100 through April), and >275 unique HCP prescribers, supporting early commercial momentum.
• Top-line results from ACACIA‑HCM (aficamten) met both co‑primary endpoints (KCCQ and peak VO2) with statistically significant treatment effects and no new safety signals, prompting plans to engage regulators and pursue a supplemental NDA for NHCM.
• Q1 net loss widened to $206M (vs. $161M year‑ago), cash and investments declined to ~$1.1B after ~$144M use in the quarter, and SG&A rose to $104.9M due to commercial launch costs, though full‑year expense guidance was maintained.
• Rapid global commercialization and regulatory progress — EU approval with a Germany launch planned in Q2, FDA acceptance of the MAPLE‑HCM sNDA (PDUFA 11/14/2026), plus ongoing MAA submissions (Switzerland, Canada) and partner progress in APAC — support international growth plans.

Cytokinetics Stock Down 0.7%

Cytokinetics stock traded down $0.55 during mid-day trading on Thursday, hitting $74.29. The company had a trading volume of 8,388,513 shares, compared to its average volume of 2,164,168. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $80.20. The business has a fifty day moving average of $64.13 and a 200 day moving average of $63.75. The stock has a market cap of $9.23 billion, a price-to-earnings ratio of -10.86 and a beta of 0.38.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CYTK. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research note on Monday, April 20th. Morgan Stanley increased their price objective on shares of Cytokinetics from $90.00 to $103.00 and gave the company an “overweight” rating in a research report on Wednesday. Leerink Partners restated an “outperform” rating on shares of Cytokinetics in a report on Tuesday, March 10th. Needham & Company LLC lifted their price objective on shares of Cytokinetics from $85.00 to $102.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Truist Financial set a $106.00 target price on shares of Cytokinetics in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.25.

Insider Activity

In related news, EVP Fady Ibraham Malik sold 12,033 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $747,850.95. Following the transaction, the executive vice president directly owned 153,902 shares of the company’s stock, valued at $9,565,009.30. This trade represents a 7.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert I. Blum sold 36,601 shares of Cytokinetics stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the sale, the chief executive officer owned 430,330 shares in the company, valued at $26,745,009.50. This represents a 7.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 169,976 shares of company stock worth $10,710,369. Corporate insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds have recently modified their holdings of the business. Kemnay Advisory Services Inc. purchased a new stake in Cytokinetics in the 4th quarter valued at approximately $27,000. Kestra Advisory Services LLC acquired a new stake in shares of Cytokinetics in the 4th quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Cytokinetics by 46.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 171 shares in the last quarter. Quarry LP purchased a new stake in shares of Cytokinetics in the third quarter valued at approximately $30,000. Finally, Advisory Services Network LLC acquired a new position in Cytokinetics during the third quarter worth $32,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.